Tyra Biosciences, Inc.

NASDAQ:TYRA

Biotechnology

Healthcare
$19.61 -2.48%

-$0.72 today

Market cap
$1.35B
Beta
0.75
P/E (TTM)
-13.4
EPS (TTM)
-$2.12
52W Low $8.98High $40.65

Volume 0.47M

Average 0.96M

TYRA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Tyra Biosciences, Inc.NASDAQ: TYRA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $39.31M (cash outflow) rose 39.6% year over year, ahead of the +36.0% change in trailing-twelve-month net income. Sequentially, it rose 16.2% from the prior quarter. Over 3 fiscal years it compounded at +29.4% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -$150.91M (+25.8%) for the fiscal year ending Dec 2026, a slowdown from the +38.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$39.31M+16.2% QoQ
Last fiscal yearDec 2025
-$119.95M+38.7% YoY
LTMMar 2026
-$131.11M+36.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.6%+42.5%+2.8 pp
1 year+38.7%+25.8%-12.9 pp
3-year CAGR+29.4%+21.4%-8.0 pp
5-year CAGR-16.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(119.95M) USD
Year-over-year change
-38.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TYRA compares with its peers on the latest reported figures

  • TYRA's LTM Mar 2026 net income of $131.11M is the 7th largest of the 11 companies compared; the peer median is $140.23M.
  • Its year-over-year change of +36.0% is the 5th highest of 11, against a peer median of +28.2%.
  • Over three fiscal years its annual growth of +29.4% compares with a peer median of +25.2%.
TYRA Competitors Peer median
Net Income for TYRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KURAKura Oncology, Inc.LTM Mar 2026$294.57M +62.0%+27.1%411.2%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$221.04M +23.7%——
VSTMVerastem, Inc.LTM Mar 2026$193.96M +30.3%+41.6%391.2%
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$157.32M +70.4%+53.9%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$145.24M +14.0%+65.2%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$135.21M +1.8%+13.3%—
TYRATyra Biosciences, Inc.LTM Mar 2026$131.11M +36.0%+29.4%—
JANXJanux Therapeutics, Inc.LTM Mar 2026$114.48M +47.3%+21.7%529.7%
NUVBNuvation Bio Inc.LTM Jun 2026$112.24M +155.3%+25.2%66.1%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M -6.4%-12.0%266.9%
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M +26.1%-14.6%44.8%
Peer median (excluding TYRA) $140.23M+28.2%+25.2%329.0%

Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.29M)(55.33M)(69.13M)(86.48M)(119.95M)
Depreciation & Amortization140K296K357K519K546K
Deferred Income Tax00000
Stock-Based Compensation2.89M10.59M13.53M22.8M28.01M
Change in Working Capital(481K)(5.85M)6.36M(729K)(1.63M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.49M0000
Other Working Capital(1.97M)(5.85M)6.36M(729K)(1.63M)
Other Non-Cash Items3K3K(1.25M)(5.88M)(2.12M)
Operating Cash Flow(23.75M)(50.29M)(50.14M)(69.77M)(95.14M)
Capital Expenditures(661K)(559K)(770K)(664K)(141K)
Acquisitions (Net)16K0000
Purchases of Investments00(143.84M)(263.62M)(101.25M)
Sales of Investments000165.89M173.86M
Other Investing Activities160000
Investing Cash Flow(645K)(559K)(144.61M)(98.4M)72.46M
Debt Repayment(9K)0000
Common Stock Issued181.22M632K1.54M200M8.1M
Common Stock Repurchased000(420K)0
Dividends Paid00000
Other Financing Activities514K002.56M0
Financing Cash Flow311.35M632K1.54M202.14M8.1M
Effect of Forex Changes0(757K)000
Net Change in Cash286.96M(50.97M)(193.21M)33.96M(14.58M)
Free Cash Flow(24.41M)(50.84M)(50.91M)(70.44M)(95.28M)

Tyra Biosciences, Inc.

NASDAQ:TYRA

Intrinsic Alpha fair value

Locked

Current Price

$19.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.